Cytokine release syndrome

By A. Shimabukuro-Vornhagen, Philipp Gödel, M. Subklewe, H. Stemmler, H. Schlößer, M. Schlaak, M. Kochanek, B. Böll, M. V. von Bergwelt-Baildon. Journal of Immunotherapy for Cancer, 2018

1,571 citations recorded by the source corpus.

During the last decade the field of cancer immunotherapy has witnessed impressive progress. Highly effective immunotherapies such as immune checkpoint inhibition, and T-cell engaging therapies like bispecific T-cell engaging (BiTE) single-chain antibody constructs and chimeric antigen receptor (CAR) T cells have shown remarkable efficacy in clinical trials and some of these agents have already received regulatory approval. However, along with growing experience in the clinical application of these potent immunotherapeutic agents comes the increasing awareness of their inherent and potentially fatal adverse effects, most notably the cytokine release syndrome (CRS). This review provides a comprehensive overview of the mechanisms underlying CRS pathophysiology, risk factors, clinical presentation, differential diagnoses, and prognostic factors. In addition, based on the current evidence we give practical guidance to the management of the cytokine release syndrome.

Subfields: Biomedical Engineering, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/ec839deeeee2f559fac4d3c796d843100fab8146

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Bo Huang
Q. Ye
Youhai H. Chen
P. N. Lagniton
X. Wan
S. Ye
Jinyan Liu
Zhixin Zhang

Citations in the corpus

The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 (2020, background): “4 Studies that focus on the inhibition of IL-1 β to reduce the cytokine storm have attracted most attention.”
COVID-19: what has been learned and to be learned about the novel coronavirus disease (2020, background): “Other immunosuppression treatments for cytokine storm include the modulation of T cell-directed immune response; the blockade of IFN-γ, IL-1, and TNF; JAK inhibition [69] ; blinatumomab [70] ; suppressor of cytokine signaling 4 [71] ; and HDAC inhibitors [72] .”
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality (2020, neutral): “[4] Shimabukuro-Vornhagen A , Gödel P , Subklewe M , Stemmler HJ , Schlößer HA , Schlaak M , et al.”
COVID-19: immunopathogenesis and Immunotherapeutics (2020, background): “Cytokine storm A dramatic increase in cytokines levels over a short time period can cause a cytokine storm, which has been regularly encountered in cancers treated with chimeric antigen receptor T (CAR-T) cells.(47,48) In patients with severe COVID-19, there is an abundance of cytokine production, i”